1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology Market Trends
Global Biologics Market-Companies-to-Action

Global Biologics Market-Companies-to-Action

  • November 2017
  • 92 pages
  • ID: 5253700
  • Format: PDF
  • By Frost & Sullivan

Summary

Table of Contents

Biopharma Companies are Increasingly Collaborating with CDMOs, CROs, and Digital and Medical Equipment Companies for Biologics Discovery and Development

This study on the "Global Biologics Market: Companies-to-Action" presents an overview of the global biologics landscape with an emphasis on the top 10 leading bio-pharma companies in the market. The study highlights the shifting focus and investments of bio-pharma companies towards biologics discovery and development, which is attributed to the growing demand for innovative therapies as well as the loss of patent exclusivity of the leading pharma products.

Across therapy areas, oncology and diabetes emerge as the key contributing segments alongside immunology and cardiovascular diseases. Several small- to mid-sized companies are increasingly focusing on oncology and immunology segments which have high unmet needs and higher acceptability for innovative therapies. Furthermore, across the biologics sub-segments, monoclonal antibodies (mAb) and bioengineered vaccines are amongst the highest contributing segments, with most companies having a strong focus on developing a mAb pipeline. On the other hand, cell and gene therapy are expected to show a strong potential, especially across the rare diseases market, with leading companies like Amgen, Sanofi, Pfizer, etc., investing in molecules in the early stages of clinical development. These molecules, if approved, have the potential of becoming key blockbuster products, propelling the market by more than 20% in the next few years.

To achieve expertise across specific therapy areas and biologic sub-segments, bio-pharma companies collaborate with Contract Development and Manufacturing Organizations (CDMOs), Contract Research Organizations (CROs), and digital and medical equipment companies that provide access to innovative proprietary technologies for research and development activities and to optimize the manufacturing process of complex biologics.

Alongside industry and academic research collaborations, companies are also focusing on partnering with IT players such as IBM Watson, Intel etc., which provide technologically advanced solutions for conducting clinical trials to support complex drug manufacturing processes, thus creating integrated business models in addition to the above mentioned strategic analysis, a detailed biologic product pipeline, and a SWOT analysis of the key players has been undertaken.

Some of the key questions answered by the study include:
• What are the current growth opportunities in biologics? What is the impact of the external environment on this market?
• Which are the leading companies that are introducing new and innovative products in the market?
• How do these companies intend to transform the industry paradigms in the next five years?
• What is their strategic focus and potential for growth?
• What are the key strategic imperatives in the biologics market?
• What are the key strategic collaborations/partnerships and investments made by the companies to stay on the growth trajectory?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Somatostatin Receptor Type 4 - Pipeline Review, H2 2019

Somatostatin Receptor Type 4 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Somatostatin Receptor Type 4 - Pipeline Review, H2 2019SummaryAccording to the recently published report ’Somatostatin Receptor Type 4 - Pipeline Review, H2 2019’; Somatostatin Receptor Type 4 (SSTR4) ...

C-X-C Chemokine Receptor Type 1 - Pipeline Review, H2 2019

C-X-C Chemokine Receptor Type 1 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

C-X-C Chemokine Receptor Type 1 - Pipeline Review, H2 2019SummaryC-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) pipeline Target ...

Leukocyte Surface Antigen CD47 - Pipeline Review, H2 2019

Leukocyte Surface Antigen CD47 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Leukocyte Surface Antigen CD47 - Pipeline Review, H2 2019SummaryAccording to the recently published report ’Leukocyte Surface Antigen CD47 - Pipeline Review, H2 2019’; Leukocyte Surface Antigen CD47 ...

Rabies - Pipeline Review, H2 2019 $ 2000 December 2019


ref:plp2017

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on